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Abstract
Background: The objective of this study was to determine the sedative load and use of sedative and psychotropic
medications among older people with dementia living in (residential) care homes.
Methods: Medication data were collected at baseline and at two further time-points for eligible residents of six
care homes participating in the EVIDEM-End Of Life (EOL) study for whom medication administration records were
available. Regular medications were classified using the Anatomical Therapeutic Chemical classification system and
individual sedative loads were calculated using a previously published model.
Results: At baseline, medication administration records were reviewed for 115 residents; medication records were
reviewed for 112 and 105 residents at time-points 2 and 3 respectively. Approximately one-third of residents were
not taking any medications with sedative properties at each time-point, while a significant proportion of residents
had a low sedative load score of 1 or 2 (54.8%, 59.0% and 57.1% at baseline and time-points 2 and 3 respectively).
More than 10% of residents had a high sedative load score (≥ 3) at baseline (12.2%), and this increased to 14.3% at
time-points 2 and 3. Approximately two-thirds of residents (66.9%) regularly used one or more psychotropic
medication(s). Antidepressants, predominantly selective serotonin re-uptake inhibitors (SSRIs), were most frequently
used, while antipsychotics, hypnotics and anxiolytics were less routinely administered. The prevalence of
antipsychotic use among residents was 19.0%, lower than has been previously reported for nursing home
residents. Throughout the duration of the study, administration of medications recognised as having prominent
sedative adverse effects and/or containing sedative components outweighed the regular use of primary sedatives.
Conclusions: Sedative load scores were similar throughout the study period for residents with dementia in each of
the care homes. Scores were lower than previously reported in studies conducted in long-term care wards which
have on-site clinical support. Nevertheless, strategies to optimise drug therapy for care home residents with
dementia which rely on clinicians external to the care home for support and medication review are required.
Background
In the United Kingdom (UK), care homes are the main
providers of long-term care for older people. They include
care homes which provide 24-hour nursing care (nursing
homes), those that provide personal care only (residential
homes), and those with mixed provision, which offer both
residential and nursing care [1]. Residential homes, which
provide the majority of long-term care for older people in
England, do not have on-site nursing provision, and rely
on primary healthcare professionals, namely general
practitioners (GPs), nurses and community pharmacists,
for meeting healthcare needs, including prescribing and
supply of medications and medication review [2].
Prescribing is one of the most common medical inter-
ventions experienced by older people resident in care
homes [3,4]. Due to multiple medical conditions and
polypharmacy (defined as the use of multiple medications
and/or administration of more medications than are
clinically indicated [5]), in addition to age-related
changes in pharmacokinetics and pharmacodynamics,
care home residents are at high risk of adverse drug
events (ADEs) [6-8]. Older people with cognitive impair-
ment are particularly susceptible to ADEs associated with
sedative and psychotropic drugs [9]. The over-use of
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psychotropic drugs (antipsychotics, antidepressants,
hypnotics, and anxiolytics) has been a particular concern
in the literature on prescribing and use of medicines in
care homes [10-17]; however, nursing homes have been
the primary focus and these studies have not been limited
to residents with cognitive impairment. Furthermore pre-
vious studies which compare psychotropic drug use
among patients with and without dementia have been
limited to specific classes of psychotropic drugs [18-21].
Recent interest has focused on the development of a
measure to quantify residents’ overall drug load [22-32].
Sedative drugs may include medications prescribed for
intentional sedation, medications with which sedation is
a prominent side-effect, or medications which yield seda-
tion as a potential ADE [33,34]. A model has been devel-
oped to quantify the cumulative effect of taking multiple
drugs with sedative properties, termed the sedative load
[35,36]. This model has been utilised thus far to examine
the sedative load among residents of long-term care
wards in Finland [33,34]. An alternative model, the Drug
Burden Index (a measure of a person’s exposure to antic-
holinergic and sedative medications), has been used to
examine exposure of residents of residential aged-care
facilities in Australia to medications with anticholinergic
and sedative properties [27,37,38]. However, to the best
of the authors’ knowledge, no studies have been con-
ducted to date which use the sedative load model to
examine prescribing of sedative medications in residents
of residential homes. The objective of this study was to
determine the sedative load and use of sedative and psy-
chotropic medications among older people with demen-
tia living in residential care homes.
Methods
The eligible study population comprised all residents
from six residential care homes participating in the EVI-
DEM-End Of Life (EOL) study for whom medication
administration records were available at baseline and at
the two further time-points (approximately sixteen weeks
apart) at which data were collected over the 12-month
data collection period. The EVIDEM-EOL study had a
prospective design, tracking the events and care experi-
enced by older people with dementia over two years, and
was undertaken between April 2008 and June 2010. Ethi-
cal approval for the EVIDEM-EOL study was granted by
the NHS Southampton and South West Hampshire
Research Ethics Committee in July 2008 (MREC Ref: 08/
H0502/74). All six care homes were registered to provide
dementia care. Care home residents who were 65 years of
age or older, and who had a documented diagnosis of
dementia, or who were determined by senior care home
staff as having cognitive impairment consistent with a
diagnosis of dementia, were eligible to participate in the
study. Written informed consent to participate was
obtained from those eligible residents who were consid-
ered to have capacity to consent. For those residents
deemed not to have capacity to consent for themselves,
written assent was obtained from a personal consultee
who, based on his/her knowledge of the resident, could
provide an opinion as to whether the resident would
have consented to his/her care notes being reviewed.
Residents with dementia whom the care home manager
thought it inappropriate to approach (for example, resi-
dents in the terminal stage of the disease), or who lacked
capacity to consent and for whom a consultee could not
be identified, were excluded from the study [39].
Medication data for each participating resident were col-
lected at baseline and at two further time-points using
medication administration records obtained from the care
home notes which detailed the medications prescribed
and administered by care home staff over the four-week
period which coincided with each data collection time-
point. The maximum number of medications prescribed
for and administered to the resident at any one time dur-
ing this four-week period was utilised to determine drug
use at each data collection time-point. All medications
were categorised using the Anatomical Therapeutic
Chemical (ATC) classification system as recommended by
the World Health Organisation [40]. As per previous
research examining sedative load of medications [33,34],
medications taken regularly were considered, while medi-
cations used on a pro re nata (prn) basis were excluded.
Medications were considered to be regularly taken if there
was a documented regular sequence of administration.
Psychotropic medications were defined as antipsychotics
(ATC classification N05A), antidepressants (N06A), hyp-
notics (N05C) and anxiolytics (N05B). The sedative load
for each resident was calculated using the sedative load
model which classifies medications into four groups
(Group 1: primary sedatives; Group 2: medications with
sedation as a prominent side-effect or preparations with a
sedating component; Group 3: medications with sedation
as a potential ADE; Group 4: all other medications with
no known sedative properties). Medications in groups 1
and 2 were given sedative ratings of 2 and 1 respectively,
and the overall sedative load for each resident was calcu-
lated using the following formula:
Sedative Loading (SL) =
n∑
k=1
SRk
where: n = number of drugs and SRk = sedative rating
for drug k [29].
Data were analysed using PASW Statistics 18.0 soft-
ware (SPSS Inc. Chicago, Illinois). Chi-squared (c2) tests
were used to compare categorical variables and Kruskal-
Wallis tests were used to compare continuous variables.
Significance was set a priori at p ≤ 0.05.
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Results
A total of 214 residents across the six care homes were
eligible for participation in the EVIDEM-EOL study. Of
these, 133 residents were recruited (62.2%). Details of
the recruitment of residential care homes and residents
have been previously published [39].
At baseline, medication administration records for 115
residents (86.5%) were reviewed; medication administra-
tion record sheets were unavailable for 18 residents as
they were archived or otherwise unobtainable as the
resident had died. The mean age of the residents was
85.8 (SD 6.8) years and 91 of these residents (79.1%)
were female; the demographic profile of residents
included in the study is detailed in Table 1. Between
two and four general practice surgeries provided services
to each care home; care homes 1, 2, 5 and 6 were each
served by two general practice surgeries, while care
homes 3 and 4 were each served by four general prac-
tice surgeries.
At baseline, eighty-six residents (74.8%) had a recorded
diagnosis of dementia in their care home notes, although
33 (38.4%) of these residents did not have a specific type
of dementia recorded. Twenty-nine residents (25.2%) did
not have a diagnosis of dementia in their care home
notes, but were determined by care home staff as having
cognitive impairment consistent with a diagnosis of
dementia. None of the care homes recorded severity of
dementia in their care notes but behavioural and com-
munication difficulties arising from having dementia
were recorded. According to the care home notes, a spe-
cific cognitive test, such as the Mini Mental State Exami-
nation (MMSE [41]), was administered to 23 residents
(20.0%). Fifty residents (43.5%) were recorded as having 3
or more co-morbidities (obtained from the care home
notes), and the mean number of long-term conditions
per resident was 2.46 (SD 1.46). The Cornell Scale for
Depression in Dementia [42] was applied by the care
home manager, or senior care home staff, for the 91 resi-
dents for whom the required data was available. Ten resi-
dents (11.0%) scored 12 or more (indicating probable
depression) and two of the care homes (3 and 4) did not
identify symptoms of depression in any of their residents.
Twenty-five residents (21.7%) were recorded as having a
diagnosis of depression in their care home notes.
The number of residents with sedative load scores
of 0 - 6 at each time-point are detailed in Table 2.
Approximately one-third of residents had a sedative
load score of 0 (33.0%, 26.8% and 28.5% at baseline and
time-points 2 and 3 respectively), and a significant pro-
portion of residents had a low sedative load score of 1
or 2 (54.8%, 59.0% and 57.1% at baseline and time-
points 2 and 3 respectively), while 12.2% had a high
sedative load (≥ 3) at baseline, increasing slightly to
14.3% at time-points 2 and 3.
Use of regular medications is outlined in Table 3.
At baseline, the mean number of regular medications
prescribed for and administered to each resident ranged
from 4.36 (SD 2.11) in care home 4 to 7.41 (SD 4.83) in
care home 2. Prevalence of polypharmacy, defined by
the National Service Framework for Older People [43]
as the prescription of four or more medications, varied
within the study population; residents in care home 6
had significantly lower levels of polypharmacy than resi-
dents in care home 5. Approximately two-thirds of resi-
dents (n = 77, 66.9%) regularly used one or more
psychotropic medication(s) [an antipsychotic, hypnotic,
anxiolytic or antidepressant].
Data relating to individual drug classes showed variabil-
ity across the study population, as presented in Table 4.
The use of antipsychotic medications ranged from 10.0%
to 41.2% across care homes, with care home 2 found to
have a considerably higher level of antipsychotic prescrib-
ing than the other homes. The most commonly used aty-
pical antipsychotic was quetiapine (n = 14, 12.2%) as
shown in Table 5. All residents taking antipsychotics in
care home 1 were prescribed conventional antipsychotics
(Tables 4 and 5).
Regular use of antidepressant medication ranged from
33.3% in care home 5 to 68.2% in care home 4. Selective
serotonin re-uptake inhibitors (SSRIs) were the most
widely used class of antidepressants across all care homes
with the exception of care home 4, where trazodone
prescribing predominated. This finding is presented in
Table 4, in which trazodone is categorised as ‘other antide-
pressants’. Twenty-one of the 22 residents in care home 4
were assessed at baseline using the Cornell Scale for
Depression in Dementia [42], and all of these residents
were classified as unlikely to be suffering from depression
(a Cornell score of less than 12), indicating that trazodone
may have been prescribed for treatment of behavioural
symptoms such as agitation. However, when assessed
using criteria for agitated/not agitated status adapted from
the Cohen-Mansfield Agitation Inventory [44], these resi-
dents did not show significantly higher scores for agitation
than residents in the other care homes (c2 test; p > 0.05).
This indicated that trazodone may have instead been used
for treatment of insomnia. Trazodone was only prescribed
for one other resident in care home 5, and was not pre-
scribed for any of the ten residents in the study who were
determined to be suffering from probable depression (a
Cornell score equal to or more than 12). Citalopram was
the most frequently prescribed SSRI in the care homes
(n = 18, 15.7%; table 5).
Regular administration of hypnotics and anxiolytics
was low, ranging from 5.0% in care home 1 to 21.4% in
care home 3, while the most frequently used hypnotic
and anxiolytic medications were temazepam (3.5%) and
lorazepam (2.6%) respectively (Table 5). Hypnotics were
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Table 1 Demographic profile for residential care home residents with dementia
Parameter Care home at each time point
1 2 3 4 5 6
BL TP2 TP3 BL TP2 TP3 BL TP2 TP3 BL TP2 TP3 BL TP2 TP3 BL TP2 TP3
Number of
residents (n)
20 20 19 17 17 16 14 14 14 22 22 21 30 27 25 12 12 10
Gender
Female [no.(%)] 18 (90.0) 18 (90.0) 17 (89.5) 14 (82.4) 14 (82.4) 13 (81.3) 12 (85.7) 12 (85.7) 12 (85.7) 20 (90.9) 20 (90.9) 20 (95.2) 19 (63.3) 17 (63.0) 18 (72.0) 8 (66.7) 8 (66.7) 7 (70.0)
Male [no.(%)] 2 (10.0) 2 (10.0) 2 (10.5) 3 (17.6) 3 (17.7) 3 (18.7) 2 (14.3) 2 (14.3) 2 (14.3) 2 (9.1) 2 (9.1) 1 (4.8) 11 (36.7) 10 (37.0) 7 (28.0) 4 (33.3) 4 (33.3) 3 (30.0)
Age
Mean 87.4 87.7 88.4 87.3 88.6 87.9 89.0 89.9 90.4 84.6 85.7 85.9 83.5 83.9 83.2 83.7 84.0 84.9
Standard
deviation
6.16 6.14 6.25 7.56 8.81 7.75 5.87 5.70 5.62 6.63 5.87 5.97 6.63 6.88 6.21 8.28 8.28 8.53
BL - baseline, TP - time point.
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Table 2 Sedative load for residential care home residents with dementia
Number of residents with sedative load at each time point
Care Home 1 Care Home 2 Care Home 3 Care Home 4 Care Home 5 Care Home 6 Total (%)
Sedative Load BL TP 2 TP 3 BL TP 2 TP 3 BL TP 2 TP 3 BL TP 2 TP 3 BL TP 2 TP 3 BL TP 2 TP 3 BL TP 2 TP 3
0 8 6 4 3 4 7 5 5 6 6 4 5 12 10 7 4 1 1 38 (33.0) 30 (26.8) 30 (28.5)
1 8 7 8 11 9 7 5 4 4 5 6 5 8 9 9 4 7 5 41 (35.7) 42 (37.5) 38 (36.2)
2 1 3 3 1 3 1 1 2 0 9 9 9 8 5 5 2 2 4 22 (19.1) 24 (21.4) 22 (21.0)
3 2 3 3 1 1 1 2 1 2 2 3 2 2 2 2 2 2 0 11 (9.6) 12 (10.7) 10 (9.5)
4 0 0 0 0 0 0 1 2 1 0 0 0 0 1 2 0 0 0 1 (0.9) 3 (2.7) 3 (2.9)
5 1 1 1 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 1 (0.9) 1 (0.9) 2 (1.9)
6 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 (0.9) 0 (0) 0 (0)
Total 20 20 19 17 17 16 14 14 14 22 22 21 30 27 25 12 12 10 115 (100.0) 112 (100.0) 105 (100.0)
BL - baseline, TP - time point
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Table 3 Use of regular medications, including sedative medications, by residential care home residents with dementia
Parameter Care home at each time point p - Value
1 2 3 4 5 6
BL TP2 TP3 BL TP2 TP3 BL TP2 TP3 BL TP2 TP3 BL TP2 TP3 BL TP2 TP3 BL TP2 TP3
Number of residents (n) 20 20 19 17 17 16 14 14 14 22 22 21 30 27 25 12 12 10
Number of regular
medications
Mean 6.70 5.10 5.11 7.41 5.88 6.00 5.79 5.57 5.57 4.36 4.41 4.33 6.17 6.74 6.88 5.17 5.75 5.90 0.07 0.13 0.10
Range 1-10 1-8 1-8 2-18 2-11 2-11 1-10 0-13 0-13 0-8 0-9 1-9 0-10 0-13 0-13 0-12 0-12 1-12
Standard deviation 3.18 2.40 2.47 4.83 3.06 3.12 3.17 3.28 3.28 2.11 2.32 2.35 2.51 3.58 3.59 3.86 3.14 3.51
Polypharmacy (>4
medications) [no.(%)]
16
(80.0)
18
(90.0)
14
(73.6)
15
(88.2)
14
(82.3)
12
(75.0)
9
(64.2)
5
(35.7)
10
(74.1)
14
(63.6)
16
(72.7)
11
(52.4)
25
(83.3)
20
(74.0)
23
(92.0)
7
(58.3)
5
(41.7)
9
(90.0)
0.02 0.19 0.08
Sedative Load
Mean 1.05 1.35 1.47 1.29 1.06 0.75 1.21 1.36 1.36 1.32 1.50 1.38 1.03 1.07 1.32 1.08 1.42 1.30 0.84 0.59 0.39
Range 0-5 0-5 0-5 0-6 0-3 0-3 0-4 0-4 0-5 0-3 0-3 0-3 0-3 0-4 0-4 0-3 0-3 0-2
Standard deviation 1.32 1.35 1.31 1.40 0.83 0.86 1.31 1.45 1.69 0.99 0.96 0.97 0.98 1.11 1.22 1.12 0.9 0.68
Antipsychotics [no.(%)] 2
(10.0)
4
(20.0)
5
(26.3)
7
(41.2)
6
(35.3)
4
(25.0)
2
(14.3)
1
(7.1)
1 (7.1) 7
(32.0)
6
(27.3)
5
(23.8)
3
(10.0)
3
(11.1)
4
(16.0)
2
(16.8)
1
(8.3)
0 0.02 0.17 0.04
Antidepressants [no.(%)] 11
(55.0)
12
(60.0)
11
(57.9)
9
(52.9)
6
(35.3)
4
(25.0)
5
(35.7)
8
(57.1)
9
(64.3)
15
(68.2)
14
(63.6)
13
(61.9)
10
(33.3)
11
(40.7)
11
(44.0)
4
(33.3)
6
(50.0)
6
(60.0)
0.29 0.41 0.35
Hypnotics and anxiolytics [no.
(%)]
1 (5.0) 1 (5.0) 1 (5.3) 1 (5.9) 0 0 3
(21.4)
3
(21.4)
2
(14.3)
2 (9.1) 2 (9.1) 2 (9.5) 4
(13.3)
5
(18.5)
5
(20.0)
2
(16.7)
3
(25.0)
2
(20.0)
0.06 0.14 0.23
BL - baseline, TP - time point
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Table 4 Use of classes of psychotropic medications by residential care home residents with dementia
Drug Class Care home data at each time point
1 2 3 4 5 6
BL TP 2 TP 3 BL TP 2 TP 3 BL TP 2 TP 3 BL TP 2 TP 3 BL TP 2 TP 3 BL TP 2 TP 3
Antipsychotics
Conventional [no.(%)] 2 (10.0) 4 (20.0) 5 (26.3) 0 0 0 1 (7.1) 1 (7.1) 1 (7.1) 1 (4.6) 1 (4.6) 1 (4.8) 1 (3.3) 1 (3.7) 2 (8.0) 1 (8.3) 1 (8.3) 0
Atypical [no.(%)] 0 0 0 7
(41.2)
6
(35.3)
4
(25.0)
1 (7.1) 0 0 6 (27.3) 5 (22.7) 4 (19.0) 2 (6.7) 2 (7.4) 2 (8.0) 1 (8.3) 0 0
Antidepressants
TCAs [no.(%)] 0 1 (5.0) 0 3
(17.7)
1 (5.9) 1 (6.3) 1 (7.1) 1 (7.1) 1 (7.1) 1 (4.6) 0 0 0 0 1 (4.0) 0 0 0
SSRIs [no.(%)] 11
(55.0)
11
(55.0)
10
(52.6)
6
(35.3)
5
(29.4)
3
(18.8)
4
(28.6)
4
(28.6)
5
(35.7)
2 (9.1) 2 (9.1) 2 (9.5) 7
(23.3)
9
(33.3)
7
(28.0)
3
(25.0)
5
(41.7)
5
(50.0)
Other antidepressants [no.
(%)]
0 0 1 (5.3) 0 0 1 (6.3) 0 3
(21.4)
3
(21.4)
12
(54.6)
12
(54.6)
11
(52.4)
3
(10.0)
2 (7.4) 3
(12.0)
1 (8.3) 1 (8.3) 1
(10.0)
Hypnotics [no.(%)] 1 (5.0) 1 (5.0) 1 (5.3) 0 0 0 2
(14.3)
2
(14.3)
1 (7.1) 1 (4.6) 1 (4.6) 1 (4.8) 2 (6.7) 2 (7.4) 2 (8.0) 2
(16.7)
3
(25.0)
2
(20.0)
Anxiolytics [no.(%)] 0 0 0 1 (5.9) 0 0 1 (7.1) 1 (7.1) 1 (7.1) 1 (4.6) 1 (4.6) 1 (4.8) 2 (6.7) 3
(11.1)
3
(12.0)
0 0 0
BL - baseline, TP - time point
TCA - tricyclic antidepressant; SSRI - selective serotonin re-uptake inhibitor
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not used by residents in care home 2, while residents in
care homes 1 and 6 did not use anxiolytics (Table 4).
At time-points 2 and 3, the study population declined to
112 and to 105 participants respectively due to drop-out
and death. The demographic data, prevalence of psycho-
tropic drug use, mean number of regular medications and
prevalence of polypharmacy are presented in Tables 1 and
2 and are similar to those presented at baseline, although
at time-point 3, there was a significant difference in mean
age of the residents in care homes 3 (90.4 years) and 5
(83.2 years) [Kruskal-Wallis test, p = 0.02]. At time-points
2 and 3, as at baseline, the most commonly used atypical
antipsychotic was quetiapine (Table 5). At time-point 2,
conventional antipsychotics were not used by residents in
care home 2 and atypical antipsychotics were not used by
residents in care homes 1, 3 and 6. In care homes 4 and 5
both conventional and atypical antipsychotics were used,
with atypical antipsychotics constituting the majority of
antipsychotic use. SSRIs were the most commonly used
antidepressants, with use ranging from 9.1% in care home
4 to 55.0% in care home 1 (Table 4). Table 5 shows that
the most frequently administered hypnotics were temaze-
pam and zopiclone (each at 3.6%), while lorazepam was
the most regularly used anxiolytic medication (2.7%).
At time-point 3, variation in the use of antipsychotics was
apparent within the population (Table 3, c2, p = 0.04).
Moreover, antipsychotics were not administered on a regu-
lar basis for any resident in care home 6. Conventional anti-
psychotics were used in care homes 1, 3, 4 and 5 but not in
care homes 2 and 6. Promazine was the most frequently
administered conventional antipsychotic (6.7%). Use of
antidepressants ranged from 25.0% in care home 2 to 64.3%
in care home 3 (Table 3). As at baseline and time-point 2,
SSRIs were the most frequently used antidepressants ran-
ging from 9.5% in care home 4 to 52.6% in care home 1
(Table 4). Tricylic antidepressants were not used in care
homes 1, 4 or 6. In care home 2, hypnotics and anxiolytics
were not administered (Table 5). Furthermore, it is
Table 5 Prevalence of the four most commonly used primary sedatives and drugs with sedation as a prominent
adverse effect/containing a sedating component among residential care home residents with dementia
Variable Drug Name All residents Care Home
1 2 3 4 5 6
n = 115 n = 20 n = 17 n = 14 n = 22 n = 30 n = 12
Baseline
Primary Sedatives [no.(%)] Promazine 5 (4.4) 2 (10.0) 0 1 (7.1) 1 (4.5) 1 (3.3) 0
Temazepam 4 (3.5) 0 0 1 (7.1) 1 (4.5) 0 1 (8.3)
Lorazepam 3 (2.6) 0 1 (5.9) 1 (7.1) 1 (4.5) 0 0
Amitriptyline 3 (2.6) 2 (10.0) 1 (5.9) 0 0 0 0
Drugs with sedation as a prominent adverse effect/ Citalopram 18 (15.7) 6 (30.0) 2 (11.8) 1 (7.1) 1 (4.5) 5 (16.7) 3 (25.0)
containing a sedating component [no.(%)] Quetiapine 14 (12.2) 0 6 (35.3) 1 (7.1) 5 (22.7) 1 (3.3) 1 (8.3)
Trazodone 12 (10.4) 0 0 0 11 (50.0) 1 (3.3) 0
Fluoxetine 8 (7.0) 3 (15.0) 3 (17.6) 1 (7.1) 1 (4.5) 0 0
Timepoint 2 n = 112 n = 20 n = 17 n = 14 n = 22 n = 27 n = 12
Primary Sedatives [no.(%)] Promazine 5 (4.4) 2 (10.0) 0 1 (7.1) 1 (4.5) 1 (3.7) 0
Temazepam 4 (3.6) 0 0 1 (7.1) 1 (4.5) 0 2 (16.7)
Zopiclone 4 (3.6) 1 (5.0) 0 0 0 2(7.4) 1 (8.3)
Lorazepam 3 (2.7) 0 0 1 (7.1) 1(4.5) 1 (3.7) 0
Drugs with sedation as a prominent adverse effect/ Citalopram 20 (17.9) 6 (30.0) 1 (5.9) 1 (7.1) 1 (4.5) 6 (22.2) 5 (41.7)
containing a sedating component [no.(%)] Trazodone 15(13.4) 0 0 3(21.4) 11 (50.0) 1 (3.7) 0
Quetiapine 11 (9.8) 0 5 (29.4) 0 5 (22.7) 1 (3.7) 0
Fluoxetine 9 (8.0) 3 (15.0) 3 (17.6) 1 (7.1) 1 (4.5) 1 (3.7) 0
Timepoint 3 n = 105 n = 19 n = 16 n = 14 n = 21 n = 25 n = 10
Primary Sedatives [no.(%)] Promazine 7 (6.7) 2 (10.0) 0 1 (7.1) 1 (4.8) 2 (8.0) 0
Temazepam 3 (2.9) 0 0 1 (7.1) 1 (4.8) 0 1 (8.3)
Zopiclone 3 (2.9) 0 0 0 0 2 (8.0) 0
Lorazepam 3 (2.9) 2 (10.0) 0 1 (7.1) 1 (4.8) 1 (4.0) 0
Drugs with sedation as a prominent adverse effect/ Citalopram 18 (15.7) 5 (26.0) 0 2 (14.3) 1 (4.8) 5 (20.7) 5 (50.0)
containing a sedating component [no.(%)] Trazodone 15 (14.3) 0 0 3 (21.4) 10 (47.6) 1 (4.0) 1 (10.0)
Quetiapine 9 (8.6) 0 4 (25.0) 0 4 (19.0) 1 (4.0) 0
Fluoxetine 8 (7.6) 3 (15.8) 2 (12.5) 1 (7.1) 1 (4.8) 1 (4.0) 0
BL - baseline, TP - time point.
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important to note that throughout the duration of this
study, use of medications which are recognised as having
prominent sedative adverse effects and/or containing seda-
tive components outweighed the regular use of primary
sedatives (Table 5).
Discussion
This study analysed the sedative load of medications
regularly taken by older people with dementia living in
six residential care homes in England, using the sedative
load model [35,36]. This model has previously been
used to examine the sedative load for residents with and
without dementia in long-term care wards [33,34]. How-
ever, prior to the current study, it has not been used in
settings where there is no on-site clinician.
The study population was more frequently adminis-
tered medications with sedation as a prominent adverse
effect or preparations with a sedating component rather
than primary sedatives. Psychotropic medications were
used on a regular basis by approximately two-thirds of
residents in this study. This complements studies in nur-
sing homes which have reported that 67% to 78% of
patients with dementia were prescribed at least one psy-
chotropic medication [21,45,46].
Despite the variation in prescribing, sedative load
scores were similar for residents across care homes at
each time-point. These scores were lower than have
been previously reported in residents of long-term care
facilities and home-dwelling older people [34,35]. How-
ever, the findings of this study support a US study of
long-term care facilities, in which residents with demen-
tia were found to have a low sedative load [26].
Whilst some studies have reported that patients with
dementia are frequently prescribed antipsychotics and
hypnotics [20,47], this study found that across all care
homes, antidepressants were more frequently used by
residents (49.8%), with antipsychotics (19.0%) and hypno-
tics and anxiolytics (11.7%) less routinely administered.
However, this difference may in part by explained by the
fact that in this study medications used on a pro re nata
(prn) basis were excluded, whilst previous studies [20,47]
included these medications.
The most commonly used antidepressants in this study
were SSRIs with citalopram being the most regularly
used. This supports the findings from previous studies
[34,46]. Fluoxetine was administered to 15% of the resi-
dents throughout the study period, despite its long half-
life which may make it inappropriate for use in older
people [48]. In care home 4, SSRIs were less commonly
used and trazodone use predominated, which may be
explained by an association between this care home and
a memory clinic. Across the study period, regular use of
hypnotics (ranging from 0% to 25.0%) was similar to
previous studies, with regular use of anxiolytics lower
than previously reported [21,34].
At 19.0%, the prevalence of antipsychotic use among
residents with dementia in this study was lower than pre-
viously reported in nursing home residents [21,34,46].
Overall, atypical antipsychotics were more commonly
used than conventional antipsychotics, reflecting pre-
scribing trends and the evidence that these medications
are superior in controlling the behavioural and psycholo-
gical symptoms of dementia [49], contribute less to the
sedative load score and are associated with fewer extra-
pyramidal side-effects. However, care home 1 was a nota-
ble exception; throughout the study period, all residents
taking antipsychotics used conventional antipsychotics.
In care home 2 at baseline, antipsychotic use was signifi-
cantly higher than in the other care homes. The resident
characteristics may have contributed to this finding, since
a high percentage of residents had three or more medical
conditions recorded in their notes.
Previous studies have reported that the most fre-
quently prescribed psychotropic medications for patients
with dementia were antipsychotics [34,46]; however in
this study antidepressants were predominantly used.
This finding merits further investigation, using a larger
population.
The underpinning knowledge for prescribing specific
psychotropic medications and their impact on the symp-
toms and quality of life experienced by patients with
dementia should be the focus of subsequent studies.
Formal trials of psychotropic drugs with low sedative
loading in care home residents with dementia should
also be undertaken. Further research is also required
into non-pharmacological alternatives to psychotropic
medication, building upon the work conducted to date
[50-63].
This study also highlights the lack of standardised diag-
nosis and staging of dementia in residential care home
residents. One-quarter of the study participants did not
have a diagnosis of dementia in their care home notes,
but were determined by care home staff as having cogni-
tive impairment consistent with a diagnosis of dementia.
Furthermore, none of the care homes recorded severity
of dementia in their care notes. There is a need for accu-
rate and standardised diagnosis and staging of dementia
in residential care homes to ensure that residents receive
appropriate and timely care, despite the potential chal-
lenges such an approach may bring.
There are a number of methodological strengths of
this study. The longitudinal design allowed examination
of the pattern of medication use over the study period,
while the use of an objective method to calculate the
cumulative sedative effect of multiple medications elimi-
nated subjective bias. Data collection directly from
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residents’ medication administration records rather than
from computerised data records facilitated the identifi-
cation of medicines which were regularly administered
rather than those which were dispensed but not actually
taken by the patient.
It is also important to consider the methodological lim-
itations of this study. Potential participants were identi-
fied either through a documented diagnosis of dementia
within residents’ care home notes or by senior care home
staff as having cognitive impairment consistent with a
diagnosis of dementia. The sedative load model presents
inherent drawbacks including the exclusion of Group 3
drugs, which have the potential to cause sedation [36].
Furthermore, this model does not consider doses and fre-
quencies of medications [34]. As with previous studies
[33,34], medications taken ‘when required’ (prn) were
excluded from the analysis. These medications could
further contribute to an individual’s sedative load.
Conclusions
To optimise drug therapy for patients with dementia
there is a need to take into consideration how individual
drugs interact and contribute to the total sedative load
score of the medications prescribed. In this study, resi-
dents with dementia were more frequently administered
drugs which had sedation as a prominent adverse effect
and/or contained a sedating component rather than pri-
mary sedatives.
Antidepressants, predominantly SSRIs, were most fre-
quently administered, while levels of use of hypnotics
and anxiolytics were lower. Sedative load scores were
found to be similar throughout the study period for resi-
dents with dementia in each of the six care homes, and
were lower than previously reported in other long-term
care settings. This study focused on older people with
dementia in care homes which have no on-site nursing
or medical provision. It demonstrates the necessity for
further research with this population and the need to
develop interventions which support ongoing review and
discussion between health service and care home provi-
ders. These interventions must recognise the complex-
ities of working across systems of care with a workforce
unqualified in medication review.
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